Please try another search
For the fiscal year ended 31 March 2022, Delta-Fly Pharma Inc revenues remained flat at Y300M. Net loss applicable to common stockholders increased 12% to Y967.3M. Revenues reflect market conditions. Higher net loss reflects Interest Income decrease of 69% to Y70K (income), Other decrease of 43% to Y120K (income). Basic Earnings per Share excluding Extraordinary Items increased from -Y187.34 to -Y178.58.
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Revenue | ||||
Gross Profit | ||||
Operating Income | -356 | -318 | -275 | -289 |
Net Income | -372 | -320 | -280 | -290 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Assets | 1780 | 490 | 787 | 906 |
Total Liabilities | 92 | 88 | 65 | 116 |
Total Equity | 1688 | 402 | 722 | 790 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | ||||
Cash From Investing Activities | ||||
Cash From Financing Activities | ||||
Net Change in Cash |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review